argenx SE revenue for the last year amounted to 1.27 B USD, the most of which — 1.23 B USD — came from its highest performing source at the moment, Antibody-based Medicines, the year earlier bringing 410.75 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought argenx SE 1.08 B USD, and the year before that — 377.66 M USD.